Aadi Bioscience Inc
NASDAQ:AADI

Watchlist Manager
Aadi Bioscience Inc Logo
Aadi Bioscience Inc
NASDAQ:AADI
Watchlist
Price: 3.6 USD -3.49% Market Closed
Market Cap: 88.8m USD
Have any thoughts about
Aadi Bioscience Inc?
Write Note

Aadi Bioscience Inc
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Aadi Bioscience Inc
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Aadi Bioscience Inc
NASDAQ:AADI
Gross Profit
$21.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Gross Profit
$37.3B
CAGR 3-Years
0%
CAGR 5-Years
8%
CAGR 10-Years
9%
Gilead Sciences Inc
NASDAQ:GILD
Gross Profit
$22B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Gross Profit
$19.7B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Gross Profit
$9.2B
CAGR 3-Years
13%
CAGR 5-Years
24%
CAGR 10-Years
29%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Gross Profit
$12B
CAGR 3-Years
1%
CAGR 5-Years
15%
CAGR 10-Years
17%
No Stocks Found

Aadi Bioscience Inc
Glance View

Market Cap
88.6m USD
Industry
Biotechnology

Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Pacific Palisades, California and currently employs 39 full-time employees. The company went IPO on 2018-06-26. The Company’s primary focus is to bring transformational therapies to cancer patients with mechanistic target of rapamycin (mTOR) pathway driver alterations such as alterations in TSC1 or TSC2 genes. The Company’s initial focus is the treatment of an ultra-rare cancer perivascular epithelioid cell tumor (PEComa). The Company’s lead product, FYARROTM, is an mTOR inhibitor bound to human albumin that has tumor accumulation, mTOR target suppression, and tumor growth inhibition over other mTOR inhibitors in preclinical models. FYARRO is an mTOR inhibitor indicated for the treatment of adult patients with advanced unresectable or metastatic perivascular epithelioid cell tumor (PEComa).

AADI Intrinsic Value
4.97 USD
Undervaluation 28%
Intrinsic Value
Price

See Also

What is Aadi Bioscience Inc's Gross Profit?
Gross Profit
21.9m USD

Based on the financial report for Sep 30, 2024, Aadi Bioscience Inc's Gross Profit amounts to 21.9m USD.

What is Aadi Bioscience Inc's Gross Profit growth rate?
Gross Profit CAGR 1Y
4%

Over the last year, the Gross Profit growth was 4%.

Back to Top